Sone-190

Understanding "SONE-190" requires looking at how sound is quantified for household appliances and acoustic engineering. What is a Sone?

| Property | Value (Pre‑clinical) | |----------|----------------------| | Molecular weight | 378 Da | | LogP | 2.1 (balanced lipophilicity) | | Brain/plasma ratio (rat) | 1.3 | | Oral bioavailability | ~65% | | Half‑life (human) | 12 h (dose‑proportional) | SONE-190

One of the most pervasive issues identified in academic research is the "Comparison Trap." Users are constantly exposed to "highlight reels"—curated, filtered versions of other people's lives. This creates a distorted reality where one’s own behind-the-scenes struggles are compared to everyone else's best moments. Understanding "SONE-190" requires looking at how sound is

The frequency was logged and relogged. A team from the university dubbed it SONE-190—the code for a sound that, for reasons of protocol, needed a number before it could have a name. The label arrived in reports and grants, in the half-formed sentences of grant-writing committees and in the terse footnotes of journal articles. But SONE-190 refused to be a footnote. It had a memory. This creates a distorted reality where one’s own

Understanding SONE-190: A Deep Dive into Digital Identifiers and Media Codes

In many technical product catalogs or acoustic reports, numbers like "190" are often part of a model-specific designation (e.g., a fan designed for 190 CFM) or a specific loudness threshold.

2.2 Clinical Development

| Phase | Design | Enrollment | Primary Endpoint | Status | |-------|--------|------------|------------------|--------| | Phase 1a | Single‑ascending dose (SAD) & multiple‑ascending dose (MAD) in healthy volunteers | 72 | Safety, tolerability, PK/PD | Completed (2025) – No serious adverse events; dose‑linear PK; CSF exposure confirmed | | Phase 1b | Randomized, double‑blind, placebo‑controlled in early‑stage FTD (C9orf72 and non‑C9 cases) | 48 | Change in CSF phosphorylated TDP‑43 (pTDP‑43) levels at 12 weeks | Completed (early 2026) – 46% mean reduction vs. 4% increase in placebo (p = 0.018) | | Phase 2a (planned) | Adaptive, multi‑arm trial with biomarker‑enriched cohorts (MRI cortical thickness, PET‑TDP‑43) | ~150 | Composite of cognitive (FTD‑RS), functional (C9‑ALS/FTD Scale) and biomarker (pTDP‑43) outcomes | Recruitment to start Q4 2026 |